Evidence map›Paper›PMID 17393321›Full record

ArticleDigestive diseases and sciences2007

Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival.

Stamatios Theocharis, Costas Giaginis, Aikaterini Parasi, Alexandra Margeli, John Kakisis, Emmanuel Agapitos, Gregorios Kouraklis

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
  13. Article
  14. Role of retinoids in the prevention and treatment of colorectal cancer.World journal of gastrointestinal oncology · 2015
    Review
  15. Chemotherapy and chemoprevention by thiazolidinediones.BioMed research international · 2015
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Stamatios TheocharisDepartment of Forensic Medicine and Toxicology, Medical School, University of Athens, 75 M. Asias str., Goudi, GR11527, Athens, Greece. theocharis@ath.forthnet.gr
Costas Giaginis
Aikaterini Parasi
Alexandra Margeli
John Kakisis
Emmanuel Agapitos
Gregorios Kouraklis
National and Kapodistrian University of Athens · GRForthnet (Greece) · GRGeneral Hospital of Nikea · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, is a key regulator of adipogenic differentiation and glucose homeostasis. PPAR-gamma ligands have recently been demonstrated to affect proliferation and differentiation in cancer cells lines. The aim of the present work was to examine PPAR-gamma expression in colon cancer cases. PPAR-gamma expression was examined immunohistochemically in 86 colon cancer cases and was correlated with clinicopathological parameters, tumor proliferative capacity, cell cycle-related molecule expression, and patient survival. Positive PPAR-gamma immunostaining was prominent in 48 of 86 cases (56%). PPAR-gamma positivity was not correlated with Dukes' stage, histological grade of differentiation, lymph node and liver metastasis, venous invasion, tumor proliferative capacity, or patient survival. A statistically significant correlation was found between PPAR-gamma and the expression of cell cycle-related molecules pRb (P < 0.016), cyclin D1 (P <0.009), p16 (P<0.032), and p21 (P<0.033), while a positive trend for cyclin E was also noted (P<0.057). The pattern, intensity, and extent of PPAR-gamma expression in positive cases were not correlated with any of the examined variables. Our findings support evidence for participation of this protein in the biological mechanisms underlying carcinogenic evolution in the colon, also suggesting the importance of specific PPAR-gamma ligands as cell cycle modulators for a future therapeutic approach in colon cancer.

Indexed as

Colonic NeoplasmsAdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorCell CycleCell Line, TumorCyclin D1Cyclin-Dependent Kinase Inhibitor ProteinsCyclin EFemaleHumansImmunohistochemistryMaleMiddle AgedAntibodies, NeoplasmBiomarkers, TumorCyclin D1Cyclin-Dependent Kinase Inhibitor ProteinsCyclin EPPAR gammaRetinoblastoma Protein

Identifiers

PMID17393321
OpenAlexW2029501542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.